|
1
|
Inaba H, Greaves M and Mullighan CG: Acute
lymphoblastic leukaemia. Lancet. 381:1943–1955. 2013.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Pui CH, Relling MV and Downing JR: Acute
lymphoblastic leukemia. N Engl J Med. 350:1535–1548.
2004.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Radadiya A, Zhu W, Coricello A, Alcaro S
and Richards NGJ: Improving the treatment of acute lymphoblastic
leukemia. Biochemistry. 59:3193–3200. 2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Ramya LN, Doble M, Rekha VPB and
Pulicherla KK: L-Asparaginase as potent anti-leukemic agent and its
significance of having reduced glutaminase side activity for better
treatment of acute lymphoblastic leukaemia. Appl Biochem
Biotechnol. 167:2144–2159. 2012.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Paul S, Kantarjian H, Sasaki K, Marx K,
Jain N, Savoy JM, DiPippo A, Jammal N, Bravo GM, Kadia T, et al:
Intrathecal prophylaxis with 12 versus 8 administrations reduces
the incidence of central nervous system relapse in patients with
newly diagnosed Philadelphia chromosome positive acute
lymphoblastic leukemia. Am J Hematol. 98:E11–E14. 2023.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kwong YL, Yeung DYM and Chan JCW:
Intrathecal chemotherapy for hematologic malignancies: Drugs and
toxicities. Ann Hematol. 88:193–201. 2009.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Khan RB, Hudson MM, Ledet DS, Morris EB,
Pui CH, Howard SC, Krull KR, Hinds PS, Crom D, Browne E, et al:
Neurologic morbidity and quality of life in survivors of childhood
acute lymphoblastic leukemia: A prospective cross-sectional study.
J Cancer Surviv. 8:688–696. 2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Taylor OA, Brown AL, Brackett J, Dreyer
ZE, Moore IK, Mitby P, Hooke MC, Hockenberry MJ, Lupo PJ and
Scheurer ME: Disparities in neurotoxicity risk and outcomes among
pediatric acute lymphoblastic leukemia patients. Clin Cancer Res.
24:5012–5017. 2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Rison RA: Ascending sensory motor
polyradiculoneuropathy with cranial nerve involvement following
administration of intrathecal methotrexate and intravenous
cytarabine in a patient with acute myelogenous leukemia: A case
report*. Cases J. 1(255)2008.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Rolf N, Boehm H, Kaindl AM, Lauterbach I
and Suttorp M: Acute ascending motoric paraplegia following
intrathecal chemotherapy for treatment of acute lymphoblastic
leukemia in children: Case reports and review of the literature.
Klin Padiatr. 218:350–354. 2006.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Tang JH, Tian JM, Sheng M, Hu SY, Li Y,
Zhang LY, Gu Q and Wang Q: Study of posterior reversible
encephalopathy syndrome in children with acute lymphoblastic
leukemia after induction chemotherapy. J Child Neurol. 31:279–284.
2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Mateos MK, Marshall GM, Barbaro PM, Quinn
MCJ, George C, Mayoh C, Sutton R, Revesz T, Giles JE, Barbaric D,
et al: Methotrexate-related central neurotoxicity: Clinical
characteristics, risk factors and genome-wide association study in
children treated for acute lymphoblastic leukemia. Haematologica.
107:635–643. 2022.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Richards S, Pui CH and Gayon P: Childhood
Acute Lymphoblastic Leukemia Collaborative Group (CALLCG).
Systematic review and meta-analysis of randomized trials of central
nervous system directed therapy for childhood acute lymphoblastic
leukemia. Pediatr Blood Cancer. 60:185–195. 2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Mauler DJ, R Richter K, Merrill S,
Valencia-Sánchez C, Krishna C and M Mrugala M: Troubleshooting an
unusual complication following intrathecal chemotherapy delivered
via Ommaya catheter: A case report. Mol Clin Oncol. 13:76–79.
2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Pan Y, Wang C, Wang H, Tao Q, Xiong S and
Zhai Z: Transverse myelopathy occurring with intrathecal
administration of methotrexate and cytarabine chemotherapy: A case
report. Oncol Lett. 11:4066–4068. 2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Hirakawa Y, Kitao A, Watanabe M, Matsumoto
S, Komaki R, Sakai R, Morimoto K, Yakushijin K and Minami H:
Irreversible intrathecal chemotherapy-induced myelopathy in a
patient with diffuse large B-cell lymphoma. Intern Med. 63:547–551.
2024.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Brock S and Jennings HR: Fatal acute
encephalomyelitis after a single dose of intrathecal methotrexate.
Pharmacotherapy. 24:673–676. 2004.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Werner RA: Paraplegia and quadriplegia
after intrathecal chemotherapy. Arch Phys Med Rehabil.
69:1054–1056. 1988.PubMed/NCBI
|
|
19
|
Laviv Y, Kasper BS and Kasper EM: Vascular
hyperpermeability as a hallmark of phacomatoses: Is the etiology
angiogenesis comparable with mechanisms seen in inflammatory
pathways? Part I: historical observations and clinical perspectives
on the etiology of increased CSF protein levels, CSF clotting, and
communicating hydrocephalus: A comprehensive review. Neurosurg Rev.
41:957–968. 2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Lamers KJB, Vos P, Verbeek MM, Rosmalen F,
van Geel WJA and van Engelen BGM: Protein S-100B, neuron-specific
enolase (NSE), myelin basic protein (MBP) and glial fibrillary
acidic protein (GFAP) in cerebrospinal fluid (CSF) and blood of
neurological patients. Brain Res Bull. 61:261–264. 2003.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Zhao M, Qiao L, Shi J, Huang F, Zhang M,
Lin X, Wang J, Geng T and Zuo H: Arachnoid involved in idiopathic
hypertrophic pachymeningitis. J Neurol Sci. 346:227–230.
2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Weiss S and Kahn Y: Intrathecal
methotrexate causing paraplegia in a middle-aged woman. Acta
Haematol. 60:59–61. 1978.PubMed/NCBI View Article : Google Scholar
|
